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Bone marrow, one of the primary lymphoid organs, harbors immune cells including hematopoietic stem cells (HSCs), lymphocytes, monocytes/macrophages, and neu-
trophils, all of which share microenvironments with bone cells such as osteoblasts, osteoclasts, and osteocytes. Bone cells were previously thought to be involved only 
in resorbing and forming bone. However, they are closely interacting with immune cells in the bone marrow, constituting the osteoimmune system, which choreographs 
all the cells in bone to regulate calcium homeostasis, bone mass/quality, and hematopoiesis in response to external stimuli (Takayanagi, 2012). Osteoimmunology started 
with the studies on bone destruction in rheumatoid arthritis (RA), the typical pathological event at the interface of bone and activated immune system. RANKL, the essen-
tial cytokine for osteoclast differentiation, was identified as the crucial link connecting T cell activation and osteoclastogenesis. RANKL signal transduction pathways are 
unraveled with a surprising similarity to immune cell signaling. In addition, numerous immunomodulatory molecules were shown to be involved in bone metabolism and 
vice versa (Takayanagi, 2007). Osteoblasts were also shown to be important in immune cell regulation as a part of the HSC niche. Here, I summarize these key subjects in 
recent advances in osteoimmunology.
Bone Cell Differentiation/Function through Bone Cell Communication Factors
To maintain the osteoimmune system, all the cells in bone marrow are regulated in a coordinated way through many soluble and membrane proteins, that are only 
poorly explored. After bone resorption, the same amount of bone should be formed to maintain the bone volume. Therefore, the factors that couple bone formation with 
resorption were regarded as important. Classical coupling factors included IGF-1 and TGF-β, which are embedded in bone matrix and released at resorption. Ephrins, 
S1P, Wnt proteins, and PDGF-BB (Xie et al., 2014) were shown to be among them. However, communication among bone cells does not occur only at the switch from 
resorption to formation. RANKL/OPG are well-known bone cell communication factors. Sost and DKKs are produced by osteocytes to regulate bone formation. Neuronal 
factors such as semaphorin/plexin emerged as important bone cell communication factors, which work in various phases of bone remodeling (Negishi-Koga and  
Takayanagi, 2012).
Bone Cells in Maintaining HSC Regulation and Oncogenic Transformation
Since it was proposed that osteoblasts are the HSC niche, many papers suggested that distinct cell populations fulfill the criteria for the HSC niche, including CXCL12-
abundant reticular (CAR) cells, Lepr+ perivascular cells, Nestin+ perivascular cells, and nonmyelinating Schwann cells (Morrison and Scadden, 2014). The role of osteo-
blasts may be more limited than initially proposed, as selective deletion of CXCL12 or SCF, essential for HSC maintenance, in osteoblasts leads to no obvious defects 
in the HSC number. However, since impairments of osteoblast or osteoclast function affect hematopoiesis or HSC mobilization, it is possible that bone cells provide an 
appropriate environment for retaining the normal HSCs in adult bone marrow. Osteoblasts are involved in HSC quiescence through secreting angiopoietin-1, osteopontin, 
or thrombopoietin. Interestingly, high expression of Jagged 1 in osteoblasts causes hematological disorders through an activation of Notch signaling in HSCs, indicat-
ing that the osteoblast niche plays a role in inhibiting the oncogenic transformation of the hematopoietic cells (Kode et al., 2014). It is also proposed that the conversion 
of latent TGF-β into active TGF-β by nonmyelinating Schwann cells regulates quiescence of HSCs. Multiple criteria to characterize niche cells, such as localization or 
molecular markers, increase the complexity of understanding bone marrow microenvironments. Further studies are required to clearly delineate the role of bone cells in 
HSC regulation under physiological and pathological settings.
Inflammation and T Cells in Bone Destruction in RA
Bone erosion in arthritis occurs at the interface of activated immune system and bone. Much has been done to understand how activated T cells induce bone erosion 
(Takayanagi, 2012). Th17 cells were found to be exclusively responsible for osteoclastogenesis in the synovium. IL-17 upregulates RANKL expression on synovial fibro-
blasts and induces inflammatory cytokines such as TNF-α, IL-6, and IL-1 from innate immune cells. These inflammatory cytokines further upregulate RANKL expression 
on synovial fibroblasts and activate osteoclast precursors. It was recently shown that Th17 cells derived from Foxp3+ T cells represent the most pathogenic T cells in 
arthritis (Komatsu et al., 2014). The role of immune cells is extended to other diseases like ankylosing spondylitis and bone formation in fracture repair and ectopic bone 
formation (Sherlock et al., 2012).
Shared Molecules between Bone and Immune Cells in Osteoclastogenic Signaling
The osteoclastogenic signal transduction is mainly dependent on RANKL/RANK and Ig-like receptor (OSCAR, PIR-A, SIRPβ1, and TREM2)-ITAM-bearing molecules 
(FcRγ and DAP12) signaling (Takayanagi, 2007). OPG is a decoy receptor for RANKL to modulate osteoclastogenesis. RANKL stimulates NF-κB and MAPKs through 
TRAF6, leading to the initial induction of NFATc1, the master transcription factor of osteoclastogenesis. In response to ITAM signal, NFATc1 translocates to the nucleus, 
makes a complex with AP-1, and binds to its own promoter, thus enabling a robust induction (autoamplification) of NFATc1. NFATc1 activity is negatively regulated by sev-
eral transcription factors, including IRF-8, MafB, and Bcl6. The expression of these negative regulators is blocked by Blimp1, a transcriptional target of NFATc1. NFATc1 
induces most of the osteoclast genes directly in cooperation with other transcription factors. Ig-like receptor cooperates with RANKL signal and activates PLCγ-mediated 
calcium signaling through the Syk-Btk/Tec/BLNK/SLP76 complex. Ligands of Ig-like receptor are not well defined, but OSCAR was shown to be a receptor for collagen 
(Barrow et al., 2011). TREM2 is activated through the association with Plexin-A1/Sema6D. The binding of the Sema3A to Nrp1/Plexin-A1 complex blocked the interac-
tion between Plexin-A1 and the TREM2/DAP12 complex (Hayashi et al., 2012). Surprisingly, most of the signaling molecules were originally identified and studied in the 
immune system. Shared molecules are not limited to osteoclastogenic genes but now extended to various genes related to bone cell differentiation/function regulators 
and communication factors.
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